(Voting Panel Chairman)
Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding The Design Portfolio Marketing Services in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also Chairman of Flathill Communications Group plc, President of The Design Portfolio Marketing Services Inc. and a member of the Investor Relations Society.
Vadim has over a decade of capital markets experience, specialising in the healthcare sector. He currently runs the research department at Northland Capital Partners Ltd, where he established a leading healthcare franchise. Previously he headed the research department at Daniel Stewart & Co. where he also established a healthcare franchise for the firm. Prior to that, he worked in research and healthcare analysis roles for Economic and Business Data Inc. and Healthcare Information Technologies Inc. in Montreal, Canada. Vadim holds a BSc in Microbiology and Immunology and a Master’s degree in Economics from McGill University.
Anne Hennecke joined MC Services in 2011. Prior to this, she held senior management positions in international pharma and biotech companies. Most recently she headed the Investor Relations and Corporate Communications department of Evotec AG for 10 years and was a member of the Company’s Executive Committee. Previously, she was responsible for Investor Relations and Corporate Communications at Schwarz Pharma AG, where she initially held management positions in the International Marketing Department.
Anne has 20 years’ experience in Financial and Strategic Communications. During her career she managed Evotec’s IPO on the Frankfurt Stock Exchange and Nasdaq, multiple M&A programmes, and major financial transactions. Anne is a pharmacist and marketing expert by training.
Tony is Director of Business Development at One Nucleus. After completing a PhD in Biochemistry at the University of Southampton in 1992, Tony undertook several years of post-doctoral research in the oncology field, primarily with the Imperial Cancer Research Fund (now CRUK). In 1997, he moved into Technology Transfer with the Medical Research Council and later (1998) University College London, at the Wolfson Institute for Biomedical Research.
In November 2003, Tony took up the post of Director of Biotechnology & Healthcare at London First, managing the London Biotechnology Network and promotion of London’s excellence in healthcare research and delivery. In May 2010 he took the London Biotechnology Network into the merger with ERBI, seeing this as the best manner in which to continue assisting member companies develop their businesses.
His role at One Nucleus encompasses the development of the membership offer to reflect the current external environment and changing needs placed upon members’ businesses. He leads on delivery of the BioWednesday events series and the annual Genesis Conference.
David Pinniger is a fund manager at Polar Capital, responsible for the Biotechnology Fund, and has over 16 years of investment experience in healthcare, specialising in biotechnology. He has managed investments across both venture and specialist funds for firms including SV Life Sciences, Abingworth and Morgan Stanley. David holds a first class honours degree in Human Sciences from the University of Oxford, and is a CFA Charterholder.
Nick is an experienced non-executive director and chairman with a background as a successful corporate financier. He has considerable experience of businesses in the healthcare, medical, biotechnology environmental and technology industries.
Until February 2016, Nick was Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company. Nick is also chairman of SEHTA, one of the largest health technology networking organisations in the UK. Until March 2013 Nick was the Chief Executive of Ipso Ventures plc, a creator and investor in early stage technology and healthcare businesses. As such he created eight businesses around university technology.
Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 18 years’ experience in Life Sciences research, covering both UK and continental European companies across a wide range of Healthcare subsectors. These include biotechnology, medical devices, diagnostics and healthcare services across both large and small-cap companies. Prior to Canaccord Genuity Julie was a member of the No.1 Extel‑rated healthcare team at Piper Jaffray. Julie started her City career at Beeson Gregory, where she became Head of Lifesciences research. Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also panel member for NIHR i4i (invention for innovation), assessing early stage medical technologies.
James has over 18 years of experience of advising UK growth companies with over 10 years dedicated to healthcare. He has overall responsibility for all corporate relationships within Peel Hunt’s healthcare franchise. Prior to joining Peel Hunt in 2009, James was a senior banker in Piper Jaffray’s European healthcare IB team with a focus on ECM and M&A mandates.
Gary is an experienced healthcare analyst having worked in the City since early 2001. He joined Zeus Capital in January 2014 and is responsible for research coverage of Life Sciences, including companies active in biotechnology, specialty pharmaceuticals, medical technology and clinical research services. He has worked on numerous IPOs and M&A mandates in the UK and Europe and has previously worked at Nomura Code Securities and KBC Peel Hunt. Prior to becoming an analyst, he managed an R&D group at a Canadian biotech company and before that he was a post‑doctoral Fellow at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. His academic training includes an MBA from the University of Durham Business School and a PhD in Immunology from the Faculty of Medicine at Monash University (Melbourne, Australia) where he also obtained a BSc.
Renee is a Managing Partner of Positive Capital Partners and was previously a Partner and COO of Omega Funds. Prior to Omega, she served as a Partner in the Venture Capital group 3i Group plc in London where, since 2005, she was responsible for managing their publicly quoted assets and European legacy healthcare portfolio. In addition, whilst at 3i, Renee structured and executed several secondary sale processes. Prior to this she was a European Group Head and MD in Investment Banking and has over 12 years of corporate finance experience with firms such as BT Alex Brown, Deutsche Bank and Lehman Brothers, where she focused on raising M&A and private and public capital for growth companies in both Europe and the US. Prior to Investment Banking, Renee worked for five years in European sales and marketing for a financial services-focused software business. Renee has a BA in Finance from Stockholm School of Economics and a MBA from INSEAD. She has significant Board experience from both private and public Board work and is presently a Board member of Scibase AB, Simparel Inc and EnXray Limited.
Amber Fennell is a healthcare communications specialist and co-founder of Consilium Strategic Communications. Amber has extensive experience in providing strategic communications support to some of the healthcare sector’s leading companies and has delivered successful PR campaigns, including significant sector IPOs, M&A and public and private fundraisings, across Europe and North America. Prior to founding Consilium, Amber was a member of M:Communications’ healthcare team and the Pharma & Biotech team at Citigate Dewe Rogerson. Amber also has a strong background in public affairs and lobbying, with experience from the European Parliament in Brussels, the United States Senate in Washington and work for the UK's BioIndustry Association. Amber has a degree in International History and Politics from Leeds University and a Masters Degree in War Studies from Kings College London.
Max joined Stifel in September 2013 as head of European healthcare equity research. Prior to this he was Chief Financial Officer of Silence Therapeutics plc. Max possesses more than 20 years of biotechnology and pharmaceutical industry experience, having held key management positions with leading development stage companies, as well as establishing several highly-rated equity research teams at a number of investment banks.
Max holds a BSc in Microbiology from the University of Kent and qualified as a Chartered Account with Arthur Andersen.
Bali joined MVM in 2012. Before joining he was a key member of Bain Capital's healthcare deal team. Prior to that he was a management consultant in Bain & Company's healthcare team. Bali obtained a degree in Clinical Medicine from Oxford University and practiced general surgery at the John Radcliffe and Addenbrooke's Hospitals. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, Cambridge University, and has published over a dozen peer reviewed papers.
Bali is a member of the boards of Onbone Oy, Wilson Therapeutics AB and Zipline Medical, Inc. and is an observer on the supervisory boards of Providence Medical Technology, Inc. and Valneva SE.
Tara has a BSc in Biochemistry and a PhD in Structural Biology, both from Imperial College London. She worked with the top-ranked European Healthcare Equity Research team at Lehman Brothers/Nomura. She then moved to Jefferies, where she spent several years as part of the European Biotechnology and Life Sciences Equity Research team. Prior to her role as the Healthcare Analyst at Shore Capital, Tara set up her own life sciences consultancy.
Jonathan was previously a biotech equity research analyst at Credit Suisse, (number one team ranked by Institutional Investor) and Evolution. Prior to joining Stifel, he spent six years in Corporate Finance at Nomura Code. Jonathan's fund-raising experience includes NicOx, GPC Biotech, Actelion, Carmat, Vernalis, Glide Pharma, Ergomed and Rex Bionics. His M&A experience includes sale of CeNeS, CBT, Biocompatibles and Protherics. Jonathan is a qualified medical doctor.
Sachin Soni is the promoter, co-founder and fund manager of Third Eye. Prior to incorporating Third Eye in 2016, Sachin worked as an Equity research Analyst on the Life Sciences team in the Securities division of Kempen & Co, a merchant bank in Amsterdam, the Netherlands, and became a Director and Head of the Life Sciences team. During his eight years at Kempen & Co from 2008 to 2016, he led a team of five, was responsible for coverage of the European Healthcare/Life Sciences sector and won Extel and Starmine awards for stock picking. He has over ten years of experience in Life Sciences, with an exposure to both private (venture capital) as well as public market investments and has been involved in multiple IPO's and secondary transactions, raising over €1.0bn for various life sciences companies.
Melanie is a Partner, Life Sciences at Instinctif Partners and she leads on financial communications within the life sciences team. She has 20 years of experience advising life sciences companies on financial communications. Prior to joining Instinctif Partners, she built and established the life sciences practice at the Hogarth Partnership. She was a Partner in the Financial Dynamics (now FTI) Life Sciences team and a Director at Merlin Financial PR. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare industries, as well as advising specialist VCs and IP commercialisation companies. Before entering business communications, she was at Price Waterhouse where she qualified as a Chartered Accountant. She has a BA in Biochemistry from the University of Oxford.
As a Principal and Analyst on the Private Transactions team, Elise provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Prior to joining Deerfield in 2010, Elise began her career in healthcare in 1987 as a Venture Capitalist and Banker at PaineWebber Inc. and was an officer of PaineWebber Development Corporation, which managed nearly $1.0bn in assets representing three PaineWebber funds and several research and development limited partnerships invested in biotechnology and high technology companies. From 1996 to 2007, Elise was a Senior Research Analyst and Managing Director in healthcare, primarily covering the biotechnology industry at PaineWebber Inc. (1996–2001) and Citigroup (2001–2007). She holds an AB in Engineering Sciences with a specialty in Biomechanics from Harvard University and an MBA from Harvard Business School.